Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for Aquestive Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.15) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics' Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.11) EPS.
Other equities research analysts have also issued research reports about the stock. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 target price on the stock. Lake Street Capital decreased their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Finally, Alliance Global Partners restated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $10.57.
Check Out Our Latest Analysis on AQST
Aquestive Therapeutics Price Performance
Aquestive Therapeutics stock traded up $0.05 during mid-day trading on Monday, reaching $2.47. 1,299,873 shares of the company traded hands, compared to its average volume of 1,584,976. Aquestive Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.80. The firm has a market capitalization of $244.21 million, a price-to-earnings ratio of -5.49 and a beta of 2.59. The firm's 50 day moving average price is $2.89 and its 200 day moving average price is $3.77.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million.
Institutional Trading of Aquestive Therapeutics
Hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its position in Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after purchasing an additional 3,821 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of Aquestive Therapeutics by 11.4% during the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after purchasing an additional 4,125 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Aquestive Therapeutics by 10.1% in the fourth quarter. Bank of Montreal Can now owns 54,300 shares of the company's stock worth $193,000 after buying an additional 4,999 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Aquestive Therapeutics by 3.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company's stock valued at $750,000 after buying an additional 7,129 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock valued at $117,000 after buying an additional 7,347 shares during the last quarter. 32.45% of the stock is owned by institutional investors.
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Further Reading
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
